Hikma Pharmaceuticals PLC · LSE:HIK
Hikma Pharmaceuticals — Investor Presentation (April 2014)
12 slides from Hikma Pharmaceuticals's investor presentation, April 2014
Slide 1: Quality
AIKMB Quality
Slide 2: Global Injectables — Delivering our strategy
Global Injectables — Delivering our strategy aN | Our business model Our manufacturing capabilities Our product portfolio and pipeline Our approach to R&D Our contract manufacturing business Quality by design Leveraging our global presence Paget
Slide 3: Our robust business model supports our growth strategy
Our robust business model supports our growth strategy AIKMA Our aA Contract products Generic injectables manufacturing Strong product portfolio and pipeline Our capabilities a Europe MENA markets geographies
Slide 4: Our extensive global manufacturing capabilities
Our extensive global manufacturing capabilities AIKMA Portugal Italy Germany Facility Vials/ ampoules Cephalosporins Lyophilised Cytotoxics - Types of ampoules / vials / Ampoules / liquids & Production bags/ lyophilised/ Vials lyophilised pre-filled syringes Primary Focus: Primary Focus: Primary Foc
Slide 5: Our strong product portfolio and opportunities for future growth
Our strong product portfolio and opportunities for future growth a A broad product portfolio > Our extensive range of products > — Sterile liquids — Cephalosporins > — Lyophilised — Hormones > Awide range of forms > — Vials — Ampoules > — Bags — Pre-filled syringes* Strong presence in niche areas —
Slide 6: Focus on bringing new, higher value products to all of our markets
Focus on bringing new, higher value products to all of our markets Frat More differentiated products Excellent prospects for growth » Products with limited competition or » Increased investment in R&D periods of exclusivity » Strong regulatory track record — 505(b)2 — Paragraph IV > Leveraging API a
Slide 7: Broadening our approach to new product development by looking beyond in-house R&D
Broadening our approach to new product development by looking beyond in-house R&D —_ ee In-house R&D . External R&D partners Enhanced product portfolio development
Slide 8: Contract manufacturing benefits the overall Injectables business
> Enables capa expansion Maximises capacity utilisation Provides good revenue > visibility Enhances technological a capabilities Drives mar: proveme! > pports business Su d Contract manufacturing benefits the overall Injectables business Provides immediate utilisation of new capacity prior to own pr
Slide 9: Our successful and growing contract manufacturing business
Competitive market positioning High customer retention & follow-on contracts Tech transter & manufacturing solutions AtoZ capabilities Our contract manufacturing business Wide range of services Analytical development & method validations Our successful and growing contract manufacturing business Hig
Slide 10: Quality is embedded in our Injectables business model
Quality is embedded in our Injectables business model > Our approach to quality — Built into culture and processes — Quality-by-design across all facilities > Maintaining the highest quality standards — Compliance with multiple regulatory authorities — local authorities in each territory and oversea
Slide 11: Leveraging our global sales and manufacturing footprint will drive growth
Leveraging our global sales and manufacturing footprint will drive A growth Page 10 10
Slide 12: Well positioned to grow our global Injectables business
Well positioned to grow our global Injectables business >» Growing global generic injectables sales — Increasing R&D — Focusing on higher value, more differentiated products — Pursuing new in- license arrangements — Product acquisitions >» Increasing contract manufacturing business > Continuing our
Hikma Pharmaceuticals — Investor Presentation (April 2014) on 6ix